Published in PLoS One on April 08, 2014
Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver. World J Hepatol (2015) 0.93
Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol (2015) 0.77
Use of rifaximin in gastrointestinal and liver diseases. World J Gastroenterol (2016) 0.75
Novel prevention strategies for bacterial infections in cirrhosis. Expert Opin Pharmacother (2016) 0.75
The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol (2017) 0.75
Rifaximin versus norfloxacin for prevention of spontaneous bacterial peritonitis: a systematic review. BMJ Open Gastroenterol (2017) 0.75
Rifaximin treatment in hepatic encephalopathy. N Engl J Med (2010) 9.60
The human oral microbiome. J Bacteriol (2010) 9.00
Liver cirrhosis. Lancet (2008) 6.11
EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol (2010) 4.55
Spontaneous bacterial peritonitis: recent guidelines and beyond. Gut (2011) 3.02
Hepatic Encephalopathy. Am J Gastroenterol (2001) 2.37
Severe sepsis in cirrhosis. Hepatology (2009) 2.33
Periodontal health status and bacteraemia from daily oral activities: systematic review/meta-analysis. J Clin Periodontol (2011) 2.10
Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology (2012) 1.92
Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology (2001) 1.91
In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother (2000) 1.65
Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology (1990) 1.63
Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol (2011) 1.62
Pathogenetic mechanisms of hepatic encephalopathy. Gut (2008) 1.59
Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One (2013) 1.51
Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs (1995) 1.45
Spontaneous bacterial peritonitis--in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998. Am J Gastroenterol (2001) 1.37
Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol (2013) 1.33
Spontaneous bacterial peritonitis with Pasteurella multocida in cirrhosis: case report and review of literature. South Med J (2004) 1.30
Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion (2006) 1.26
Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis (1993) 1.21
Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology (2010) 1.20
High prevalence of antibiotic-resistant bacterial infections among patients with cirrhosis at a US liver center. Clin Gastroenterol Hepatol (2012) 1.15
Failure of current antibiotic first-line regimens and mortality in hospitalized patients with spontaneous bacterial peritonitis. Infection (2009) 1.14
Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect (2004) 1.14
Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. J Hepatol (2011) 1.05
A recent evaluation of empirical cephalosporin treatment and antibiotic resistance of changing bacterial profiles in spontaneous bacterial peritonitis. Dig Dis Sci (2009) 1.00
Culture-negative neutrocytic ascites: a less severe variant of spontaneous bacterial peritonitis. J Hepatol (1990) 1.00
The impact of 16S ribosomal RNA-based phylogeny on the taxonomy of oral bacteria. Periodontol 2000 (1994) 0.99
Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res (1986) 0.93
Inflammation and hepatic encephalopathy. Arch Biochem Biophys (2013) 0.92
The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol (2012) 0.91
Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps. Antimicrob Agents Chemother (2012) 0.90
Rifaximin intake leads to emergence of rifampin-resistant staphylococci. J Infect (2010) 0.89
Ascitic microbiota composition is correlated with clinical severity in cirrhosis with portal hypertension. PLoS One (2013) 0.88
Bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. World J Hepatol (2012) 0.87
Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol (2012) 0.87
Selective medium for Pasteurella multocida and its use to detect oropharyngeal carriage in pig breeders. J Clin Microbiol (1990) 0.77
Effects of rifaximin on bacterial translocation in thioacetamide-induced liver injury in rats. Inflammation (2012) 0.76
The role of miRNA-34a as a prognostic biomarker for cirrhotic patients with portal hypertension receiving TIPS. PLoS One (2014) 0.81
Soluble TNF-alpha-receptors I are prognostic markers in TIPS-treated patients with cirrhosis and portal hypertension. PLoS One (2013) 0.80
CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt. J Hepatol (2014) 0.79
Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Liver Int (2015) 0.79
A farnesoid X receptor polymorphism predisposes to spontaneous bacterial peritonitis. Dig Liver Dis (2014) 0.79
Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis. Gut (2015) 0.78
Statins improve NASH via inhibition of RhoA and Ras. Am J Physiol Gastrointest Liver Physiol (2016) 0.76
Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis. PLoS One (2015) 0.75